Abstract:EGFR tyrosine kinase inhibitors (TKIs) have become a major treatment modality for advanced patients with NSCLC who have EGFR mutations.1Alexander P.B. Wang X.F. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies.Front Med. 2015; 9: 134-138Crossref PubMed Scopus (33) Google Scholar Acquired resistance to EGFR TKIs ultimately develops and approximately half of resistant mechanisms to the first- and second-generation EGFR TKI were associated with EGFR T790M.2Yu H.A. Riely G.J. Lovly C.M. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Clin Cancer Res. 2014; 20: 5898-5907Crossref PubMed Scopus (72) Google Scholar AZD9291 (osimertinib), a third-generation EGFR TKI, has been approved as a standard treatment for EGFR T790M-mutant NSCLC, but acquired resistance inevitably develops after 9 to 13 months.3Mok T.S. Wu Y.L. A M.-J. et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.N Engl J Med. 2017; 376: 629-640Crossref PubMed Scopus (2185) Google Scholar Resistant mechanisms are known to result from secondary mutations in EGFR, bypass or alternative pathway activation, downstream pathway activation, and histologic transformation.4Cross D.A. Ashton S.E. Ghiorghiu S. et al.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Cancer Discov. 2014; 4: 1046-1061Crossref PubMed Scopus (1449) Google Scholar In vitro study has shown that double mutations EGFR L718V and L858R rendered resistance to erlotinib, gefitinib, and osimertinib, but remained sensitive to afatinib.5Liu Y. Li Y. Ou Q. et al.Acquired EGFR L718V mutation mediates resistance to osimertinib in non–small cell lung cancer but retains sensitivity to afatinib.Lung Cancer. 2018; 118: 1-5Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar The clinical effect of afatinib in patients with EGFR L718V/L858R mutations was unclear. Herein, we report the first case in which co-existing EGFR L718V and L858R confer resistance to osimertinib but retain sensitivity to afatinib in a patient with NSCLC. A 45-year-old Chinese male with 10 years of smoking history presented with cough and dyspnea. Computed tomography (CT) scan showed a left lung upper lobe mass with invasion of mediastinal, bilateral supraclavicular and intrapulmonary lymph nodes in May 2016. Pathologic examination of the supraclavicular lymph node confirmed moderate and highly differentiated adenocarcinoma. Amplification refractory mutation system – polymerase chain reaction genomic testing revealed EGFR L858R+. The patient commenced on first-generation EGFR TKI gefitinib (250 mg per day) at June 2016 and tolerated it well. He underwent local resection of cancer in the left upper lobe 2 month later and maintained treatment of gefitinib for 20 months. CT scan revealed multiple right lung and lymph nodes metastases in February 2018, leading to progressive disease. Molecular analysis with circulating tumor DNA next-generation sequencing (Kingmed Diagnostics, Guangzhou, China) identified the emergence of EGFR T790M. Therefore, the patient was started on osimertinib (80 mg per day) at March 2018. Approximately 8 months later, imaging presented increasing lesions in right lung (Fig. 1A). Repeated next-generation sequencing on CT-guided biopsy specimen (lung tissue) identified the emergence of EGFR L718V (variant allele frequency = 82.05%), in conjunction with L858R (c.2573T>G, 90.18%) and EGFR amplification, without T790M mutation. Based on the preclinical studies, the patient received afatinib (40 mg per day) starting on January 8, 2019. CT scans after 1 month of afatinib treatment showed obvious shrinkage in mediastinal lymph nodes, contributing to partial response (Fig. 1B). Partial response was further confirmed at the third month (Fig. 1C). The patient complained of deteriorating headache. Several enhancing foci were observed through cerebral magnetic resonance imaging, evaluated as brain metastases. Therefore, he underwent palliative local brain radiotherapy at a total dose of 40 Gy (in 4-Gy fractions) and received one cycle of bevacizumab (400 mg) for prevention of brain edema. Chest CT 5 months (Fig. 1D) after afatinib commencement showed consistent disease control. The patient continued on the afatinib treatment until now the cutoff day, July 6, 2019, yielding progression-free survival beyond the central nervous system of at least 6 months. No intolerant adverse events exist. To our best knowledge, this is the first case to report acquired EGFR L718V mutation and loss of T790M-mediated resistance to osimertinib in a patient with NSCLC who responded to afatinib. Furthermore, our findings highlight the importance of dynamic genetic monitoring to understand resistant mechanisms and tailor precision therapies for better clinical outcomes. This work was financially supported by National Key R&D Program of China (2016YFC0905500, 2016YFC0905503), Chinese National Natural Science Foundation (81772476, 81602005, 81872499, and 81702283), Science and Technology Program of Guangdong (2017B020227001), Science and Technology Program of Guangzhou (201607020031), and the Strategic Priority Research Program of the Chinese Academy of Science (No. XDA 12020101 to J.D.). Drs. Fang and Gan contributed equally to this work.

Successful Treatment with Osimertinib and Its Subsequent Resistance Mechanism in a Patient with Non-Small-cell Lung Cancer Harboring Acquired EGFR T790M Mutation after Recovery from AC0010-induced Interstitial Lung Disease

Successful Treatment of EGFR T790M-mutant Non-Small Cell Lung Cancer with Almonertinib after Osimertinib-Induced Interstitial Lung Disease: a Case Report and Literature Review

An Advanced Non-Small Cell Lung Cancer Patient with Epidermal Growth Factor Receptor Sensitizing Mutation Responded to Toripalimab in Combination with Chemotherapy after Resistance to Osimertinib: a Case Report

Osimertinib for Egfr T790m Positive Non-Small Cell Lung Cancer-Making It Happen, Turning Good Idea into Great Results

MA15.10 Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

A Consensus on the Role of Osimertinib in Non-Small Cell Lung Cancer from the AME Lung Cancer Collaborative Group

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review

Significant Benefits of Osimertinib in Treating Acquired Resistance to First-Generation EGFR-TKIs in Lung Squamous Cell Cancer: A Case Report.

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient

Case Report: Primary Resistance to Osimertinib in Erlotinib-Pretreated Lung Adenocarcinoma with EGFR T790 M Mutation.

Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient with NSCLC Who Responded to Afatinib

Data from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

Durable Response to Osimertinib in an Advanced Lung Adenocarcinoma Patient with an Uncommon EGFR T854A Mutation: A Case Report

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.

Triple Administration of Osimertinib Followed by Chemotherapy for Advanced Lung Adenocarcinoma: A Case Report